The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome

Basit Öğe Kaydı
dc.contributor.authorGül, Özgür Barış
dc.contributor.authorSomunkıran, Aslı
dc.contributor.authorYücel, Oğuz
dc.contributor.authorDemirci, Fuat
dc.contributor.authorÖzdemir, İsmail
dc.date.accessioned2020-04-30T23:32:55Z
dc.date.available2020-04-30T23:32:55Z
dc.date.issued2008
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000252662200004en_US
dc.descriptionPubMed: 17618446en_US
dc.description.abstractObjective Women with polycystic ovary syndrome (PCOS) have multiple risk factors for cardiovascular disease. The cardiovascular risk marker homocysteine (Hcy) is elevated in women with PCOS. This prospective study investigated the effect of oral contraceptives containing ethinyl estradiol-cyproterone acetate (EE-CA) on serum Hcy levels in women with PCOS. Study design A total of 30 women with PCOS were enrolled in this prospective study. The diagnosis of PCOS was made according to the criteria of the Rotterdam PCOS consensus workshop group. All women took oral contraceptives containing EE/CA (35 mu g/2 mg) for 3 months. Serum samples for Hcy, lipid profile and hormones were obtained during the early follicular phase (days 3-5) of the spontaneous or progestin-induced bleeding at baseline, and after the third treatment cycle. Results Three months of EE-CA therapy significantly decreased the Hcy levels from 55.97 +/- 16.04 to 54.03 +/- 16.15 (P = 0.01). A significant correlation was observed between the Hcy and total and free testosterone levels (r = 0.44, P = 0.015 and r = 0.46, P = 0.001 respectively). Conclusions Although the decrease in Hcy levels with EE-CA therapy was statistically significant, further studies are necessary to determine the clinical benefit of this treatment.en_US
dc.identifier.doi10.1007/s00404-007-0401-xen_US
dc.identifier.endpage30en_US
dc.identifier.issn0932-0067
dc.identifier.issn1432-0711
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage25en_US
dc.identifier.urihttps://doi.org/10.1007/s00404-007-0401-x
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4852
dc.identifier.volume277en_US
dc.identifier.wosWOS:000252662200004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofArchives Of Gynecology And Obstetricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPCOSen_US
dc.subjecthomocysteineen_US
dc.subjectoral contraceptive therapyen_US
dc.titleThe effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndromeen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
4852.pdf
Boyut:
286.58 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu